Short Wave Short Wave

An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist

Nov 9, 2026 · 12m

Summary

Host Emily Kwong discusses the intersection of GLP-1 drugs and pregnancy with OBGYN Amy Valente, who contributed to new ACOG guidelines. They explore the "Ozempic baby" trend, noting that some GLP-1s may reduce the efficacy of oral contraceptives. The episode also covers how these medications benefit patients with PMOS and diabetes by improving fertility and pre-pregnancy health, while emphasizing the need to stop taking them before conception to ensure fetal safety.

Topics discussed

Intro: Con Ed sponsor and episode premise The 'Ozempic Baby' phenomenon and patient confusion Patient questions on stopping or restarting GLP-1s AOG releases new guidance on GLP-1s and pregnancy Sponsor announcements: Citi, Viking, and The Visitors How GLP-1s affect oral contraceptive efficacy Recommendations for alternative birth control methods Benefits of GLP-1s for patients with PMOS (PCOS) GLP-1s and diabetes management before pregnancy Challenges of maintaining health off medication AOG guidance: When to stop GLP-1s before pregnancy Weight rebound and safety concerns during pregnancy Nutritional risks of GLP-1s for fetal development Why pregnancy research lags behind drug development Closing remarks and show notes link Credits and production team Sponsor announcements: Google Workspace and Mint Mobile

More from Short Wave

This gas station drug acts like opioids. It’s getting harder to buy
Nov 20, 2026
How a viral video gave a huge boost to new gene therapy
Nov 18, 2026
How bird poop and manta rays sustain a pristine coral reef
Nov 17, 2026
Are your body clocks off? Meet ‘circadian depression’
Nov 16, 2026
AI could help hospitals diagnose PTSD in real time
Nov 13, 2026
Listen ad-free on Castria